AI assistant
Hansa Biopharma — Director's Dealing 2016
Apr 6, 2016
3057_rns_2016-04-06_ac40138f-4fd8-4906-b168-fc5b954c817b.pdf
Director's Dealing
Open in viewerOpens in your device viewer
- PRESS RELEASE - April 6, 2016
Proposed chairman Ulf Wiinberg buys shares in Hansa Medical
Ulf Wiinberg has purchased 75,000 shares in Hansa Medical AB (publ) during April 5-6, 2016. He has been nominated by the company's nomination committee as new chairman of the board. The annual general meeting will be held on May 11.
About Hansa Medical AB
Hansa Medical is a biopharmaceutical company focusing on novel immunomodulatory enzymes. The lead project IdeS is an antibody-degrading enzyme in clinical development, with potential use in transplantation and rare autoimmune diseases. Additional projects focus on development of new antibody modulating enzymes, as well as HBP, a diagnostic biomarker for prediction of severe sepsis at emergency departments that is already introduced on the market. The company is based in Lund, Sweden. Hansa Medical's share (ticker: HMED) is listed on Nasdaq Stockholm's main market.
For further information, please contact:
Göran Arvidson, CEO Hansa Medical AB Mobile: +46 70-633 30 42 E-mail: [email protected] www.hansamedical.com
The information in this press release is disclosed pursuant to the Swedish Securities Markets Act and/or the Swedish Financial Instruments Trading Act. The information was released for public disclosure on April 6, 2016 at 15.00 CET.